931 Shares in Laboratory Co. of America Holdings (NYSE:LH) Purchased by Patriot Financial Group Insurance Agency LLC

Patriot Financial Group Insurance Agency LLC bought a new position in shares of Laboratory Co. of America Holdings (NYSE:LH) in the third quarter, Holdings Channel.com reports. The institutional investor bought 931 shares of the medical research company’s stock, valued at approximately $208,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of LH. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Laboratory Co. of America by 3.4% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 16,581 shares of the medical research company’s stock worth $3,622,000 after purchasing an additional 550 shares during the period. First Trust Direct Indexing L.P. lifted its holdings in shares of Laboratory Co. of America by 2.4% during the first quarter. First Trust Direct Indexing L.P. now owns 4,291 shares of the medical research company’s stock worth $937,000 after purchasing an additional 100 shares during the period. Tempus Wealth Planning LLC lifted its holdings in Laboratory Co. of America by 8.9% in the first quarter. Tempus Wealth Planning LLC now owns 1,616 shares of the medical research company’s stock valued at $353,000 after acquiring an additional 132 shares during the period. American National Bank & Trust Co. VA purchased a new stake in Laboratory Co. of America in the 1st quarter worth approximately $284,000. Finally, Sequoia Financial Advisors LLC grew its stake in shares of Laboratory Co. of America by 54.6% during the 1st quarter. Sequoia Financial Advisors LLC now owns 135,161 shares of the medical research company’s stock worth $29,527,000 after purchasing an additional 47,744 shares during the period. Institutional investors and hedge funds own 95.94% of the company’s stock.

Insiders Place Their Bets

In other Laboratory Co. of America news, EVP Lance Berberian sold 12,093 shares of the firm’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $229.10, for a total value of $2,770,506.30. Following the completion of the sale, the executive vice president now directly owns 15,921 shares of the company’s stock, valued at $3,647,501.10. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Lance Berberian sold 12,093 shares of Laboratory Co. of America stock in a transaction on Monday, August 5th. The stock was sold at an average price of $229.10, for a total transaction of $2,770,506.30. Following the transaction, the executive vice president now owns 15,921 shares in the company, valued at $3,647,501.10. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 2,000 shares of Laboratory Co. of America stock in a transaction on Monday, August 19th. The stock was sold at an average price of $227.05, for a total value of $454,100.00. Following the transaction, the executive vice president now owns 3,670 shares in the company, valued at approximately $833,273.50. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,679 shares of company stock valued at $6,946,306. Insiders own 0.85% of the company’s stock.

Laboratory Co. of America Trading Up 1.1 %

Shares of LH opened at $230.56 on Thursday. Laboratory Co. of America Holdings has a 52-week low of $191.97 and a 52-week high of $239.50. The stock has a market cap of $19.36 billion, a PE ratio of 44.60, a price-to-earnings-growth ratio of 1.77 and a beta of 1.05. The firm’s fifty day moving average is $222.71 and its two-hundred day moving average is $212.87. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.66.

Laboratory Co. of America (NYSE:LH) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $3.50 earnings per share for the quarter, topping analysts’ consensus estimates of $3.48 by $0.02. The firm had revenue of $3.28 billion for the quarter, compared to analyst estimates of $3.26 billion. Laboratory Co. of America had a net margin of 3.43% and a return on equity of 15.27%. Laboratory Co. of America’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period in the previous year, the business posted $3.38 earnings per share. Research analysts forecast that Laboratory Co. of America Holdings will post 14.53 earnings per share for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 13th. Investors of record on Tuesday, November 26th will be given a dividend of $0.72 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $2.88 dividend on an annualized basis and a yield of 1.25%. Laboratory Co. of America’s payout ratio is 55.71%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on LH shares. UBS Group boosted their target price on shares of Laboratory Co. of America from $260.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Evercore ISI lowered their target price on shares of Laboratory Co. of America from $250.00 to $240.00 and set an “in-line” rating on the stock in a research note on Tuesday, September 24th. Robert W. Baird upped their price target on Laboratory Co. of America from $282.00 to $289.00 and gave the stock an “outperform” rating in a report on Friday, October 25th. StockNews.com downgraded Laboratory Co. of America from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. Finally, Truist Financial boosted their price objective on Laboratory Co. of America from $255.00 to $275.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Five research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $253.92.

Laboratory Co. of America Profile

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.